Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease

Gaultier, Gabrielle N.; McCready, William; Ulanova, Marina

doi:10.1016/j.vaccine.2019.05.036

Cited by 4 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present study are consistent with the results of research works which have been done by Nix et al ( 6) and Gaultier et al (18) that ESRD patients undergoing hemodialysis are at high risk of Hib infection and suggested Hib vaccination in these patients.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Natural Acquired Immunity Against Haemophilus influenzae Type-B in Patients Undergoing Hemodialysis Jahrom, Iran, 2022

et al. 2023

View full text Add to dashboard Cite

Background: End stage renal disease (ESRD) patients who undergo hemodialysis treatment suffer from immune system disorders. The immunodeficiency of these patients makes them prone to various infections. Objectives: To investigate the prevalence of naturally acquired immunity against Haemophilus influenzae type-B (Hib) and its association with the duration of dialysis treatment, gender, and age of patients in hemodialysis patients in Jahrom city, Iran. Methods: This cross-sectional descriptive was conducted on ESRD patients undergoing hemodialysis treatment, referred to Jahrom Hemodialysis Center, March - August,2022. In order to determine the presence or absence of an immunity to Hib in the patients, the qualitative level of anti-Hib Polyribosyl-ribitol-phosphate (anti-Hib PRP) antibodies in the serum of the patients were determined using the ELISA test using a specialized commercial kit. SPSS-21 was used to analyze the data. The chi-square test, univariate and multivariable logistic regression were used for data analysis. Results: The prevalence of naturally acquired immunity to Hib in patients was 26.13% (10.22% short-term immunity, 15.91% long-term immunity). A significant relationship was found between the prevalence of long-term immunity to Hib in patients and the number of dialysis sessions three times per week (P < 0.001). Conclusions: Considering that hemodialysis patients in Iran are not vaccinated against Hib, 26.13% prevalence of natural immunity against Hib indicates the same prevalence of Hib infection history in hemodialysis patients. A case-control study with a large sample size on hemodialysis patients is recommended to accurately determine the prevalence of Hib and to decide whether to implement a Hib vaccination program in these patients.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Gaultier et al reported that 100% of hemodialysis patients had natural anti-Hib antibodies (without vaccination) in their serum and concluded that Hib is one of the infectious agents in these patients (18).…”

Section: Discussionmentioning

confidence: 99%

Natural Acquired Immunity Against Haemophilus influenzae Type-B in Patients Undergoing Hemodialysis Jahrom, Iran, 2022

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The antibody response to Hepatitis B vaccine is muted in CKD individuals, with low seroconversion and rapid reduction in titers post-vaccination (265). Further, in Hemophilus influenza A-vaccinated CKD patients, there are reduced absolute B cell numbers and less functional bactericidal antigen-specific IgG and IgM (266). In a recent study, aiming to elucidate the role of the T-cell inhibitory receptor CTLA-4 in pathogenesis of glomerulonephritis, a major cause of CKD, levels of IgM inversely correlated with lower CTLA-4, as did IgG and IgA to a lesser extent, with the proposition that this may reflect inappropriate IgM function in ESRD (267).…”

Section: Antibody Isotypes and Subclasses In Chronic Kidney Diseasementioning

confidence: 99%

An Inflammatory Story: Antibodies in Tuberculosis Comorbidities

McLean

Kent

et al. 2019

Front. Immunol.

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) resides in a quarter of the world's population and is the causative agent for tuberculosis (TB), the most common infectious reason of death in humans today. Although cellular immunity has been firmly established in the control of Mtb, there is growing evidence that antibodies may also modulate the infection. More specifically, certain antibody features are associated with inflammation and are divergent in different states of human infection and disease. Importantly, TB impacts not just the healthy but also those with chronic conditions. While HIV represents the quintessential comorbid condition for TB, recent epidemiological evidence shows that additional chronic conditions such as diabetes and kidney disease are rising. In fact, the prevalence of diabetes as a comorbid TB condition is now higher than that of HIV. These chronic diseases are themselves independently associated with proinflammatory immune states that encompass antibody profiles. This review discusses isotypes, subclasses, post-translational modifications and Fc-mediated functions of antibodies in TB infection and in the comorbid chronic conditions of HIV, diabetes, and kidney diseases. We propose that inflammatory antibody profiles, which are a marker of active TB, may be an important biomarker for detection of TB disease progression within comorbid individuals. We highlight the need for future studies to determine which inflammatory antibody profiles are the consequences of comorbidities and which may potentially contribute to TB reactivation.

show abstract

“…Among immune abnormalities, this group has noticeable alterations in B cells and B-cell function. We have recently found that patients with CKD had decreased absolute numbers of B cells and B-cell subpopulations compared to healthy controls [36]. Pahl et al (2010) also found decreased numbers of B cells in CKD patients, suggesting that B-cell lymphopenia in patients with CKD was due to uremia [37].…”

Section: Discussionmentioning

confidence: 94%

“…Non-adherent cells were washed with RPMI 1640 medium with L-glutamine supplemented with 1% antibiotic-antimicotic and 10% FBS (10% supplemented medium) and re-suspended at 2 X 10 6 cells/ mL in 10% supplemented medium. From the cell suspension, 200, 000 cells were immunostained with PE Mouse Anti-Human CD19, APC Mouse Anti-Human IgM, PerCP-Cy™5.5 Mouse Anti-Human CD27, and FITC Mouse Anti-Human CD5 (BD Biosciences) at 4°C for 1 h. Samples were analyzed with BD FACSCalibur™ Flow Cytometer and CELLQUEST PRO software (BD Biosciences) to determine proportions of B cells (CD19+) and subpopulations: naïve (CD27-IgM+), IgM memory (CD27 + IgM+), class switched (CD27-IgM-), class switched memory (CD27 + IgM-), CD5+ and CD5-B cells as previously described [36]. Purity of CD19+ gated B cells was verified by counterstaining cells with FITC Mouse Anti-Human CD3 and PerCP-Cy™5.5 Mouse Anti-Human CD14 (BD Biosciences).…”

Section: Analysis Of B Cellsmentioning

confidence: 99%

The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease

2019

Self Cite

View full text Add to dashboard Cite

BackgroundWhile the 23-valent pneumococcal polysaccharide vaccine (PPV23) is routinely used in Canada and some other countries to prevent pneumococcal infection in adults with chronic kidney disease (CKD), patients develop a suboptimal antibody response to PPV23 due to their immune dysfunction. The 13-valent pneumococcal conjugate vaccine (PCV13) has superior immunogenicity in some categories of immunocompromised adults; however, its effect on the immune response in CKD patients has only been addressed by two recent studies with conflicting results. The effect of PPV23 or PCV13 on B cells in these patients has not been previously studied. We studied the absolute numbers and proportions of B cells and subpopulations in two groups of adult patients with severe CKD pre- and 7 days post-immunization with PCV13: pneumococcal vaccine naïve and previously immunized with PPV23 (over one year ago).ResultsPPV23 immunized patients had significantly lower proportions and absolute numbers of class switched memory (CD19 + CD27 + IgM-), as well as lower absolute numbers of IgM memory (CD19 + CD27 + IgM+) and class switched B cells (CD19 + CD27-IgM-) compared to PPV23 naïve patients. Following PCV13 immunization, the differences in absolute numbers of B-cell subpopulations between groups remained significant. The PPV23 immunized group had higher proportions of CD5- B cells along with lower proportions and absolute numbers of CD5+ B cells compared to PPV23 naïve patients both pre- and post-immunization with PCV13. However, previous PPV23 immunization did not have a noticeable effect on the numbers of total IgG or serotype 6B and 14 specific antibody-secreting cells detected 7 days post-immunization with PCV13. Nevertheless, fold increase in anti-serotype 14 IgG concentrations 28 days post-PCV13 was greater in PPV23 naïve than in previously immunized patients.ConclusionsThe results suggest that immunization with PPV23 may result in long-term changes in B-cell subpopulations such as increased prevalence of CD5- B cells and decreased prevalence of class switched memory B cells in the peripheral blood. Because previous immunization with PPV23 in patients with CKD is associated with a significant decrease in the total class switched memory B cells in response to subsequent immunization with PCV13, this may reduce PCV13 immunogenicity in the setting of PPV23 followed by PCV13.Trial registrationRegistered February 24, 2015 at ClinicalTrials.gov (NCT 02370069).

show abstract

Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease

Cited by 4 publications

References 37 publications

Natural Acquired Immunity Against Haemophilus influenzae Type-B in Patients Undergoing Hemodialysis Jahrom, Iran, 2022

Natural Acquired Immunity Against Haemophilus influenzae Type-B in Patients Undergoing Hemodialysis Jahrom, Iran, 2022

An Inflammatory Story: Antibodies in Tuberculosis Comorbidities

The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease

Contact Info

Product

Resources

About